Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2 -Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient.
Autorzy:
Meijer TG; Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Department of Pathology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands. MartensJWM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. Prager-van der Smissen WJC; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. Verkaik NS; Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands. Beaufort CM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. van Herk S; Oncode Institute, 3521 AL Utrecht, The Netherlands.; Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. Robert-Finestra T; Oncode Institute, 3521 AL Utrecht, The Netherlands.; Department of Developmental Biology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. Hoogenboezem RM; Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. Ruigrok-Ritstier K; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. Paul MW; Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands. Gribnau J; Oncode Institute, 3521 AL Utrecht, The Netherlands.; Department of Developmental Biology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. Bindels EMJ; Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. Kanaar R; Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands. Jager A; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. van Gent DC; Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands. Hollestelle A; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2024 Feb 10; Vol. 16 (4). Date of Electronic Publication: 2024 Feb 10.
Expression and Localization of Ferritin-Heavy Chain Predicts Recurrence for Breast Cancer Patients with a BRCA1/2 Mutation.
Autorzy:
Qu S; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. Timmermans AM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. Heemskerk-Gerritsen BAM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. Trapman-Jansen AMAC; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. Broeren-Foekens R; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. Prager-van der Smissen WJC; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. El Hassnaoui H; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. van Tienhoven T; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. Bes-Stobbe CK; Pathan BV, Kleiweg 500, 3045 PM Rotterdam, The Netherlands. Westenend PJ; Laboratory of Pathology, 3318 AL Dordrecht, The Netherlands. van Deurzen CHM; Department of Pathology, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands. MartensJWM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. Hooning MJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. Hollestelle A; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2023 Dec 20; Vol. 16 (1). Date of Electronic Publication: 2023 Dec 20.
Circulating Tumour DNA as Biomarker for Colorectal Liver Metastases: A Systematic Review and Meta-Analysis.
Autorzy:
Wullaert L; Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands. van Rees JM; Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands. MartensJWM; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands. Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands. Grünhagen DJ; Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands. Wilting SM; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands. Verhoef C; Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Pokaż więcej
Źródło:
Cells [Cells] 2023 Oct 25; Vol. 12 (21). Date of Electronic Publication: 2023 Oct 25.
Liquid Biopsies for Colorectal Cancer and Advanced Adenoma Screening and Surveillance: What to Measure?
Autorzy:
Eikenboom EL; Department of Clinical Genetics, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands.; Department of Gastroenterology & Hepatology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands. Wilting SM; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands. Deger T; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands. Srebniak MI; Department of Clinical Genetics, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands. Van Veghel-Plandsoen M; Department of Clinical Genetics, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands. Boers RG; Department of Developmental Biology, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands. Boers JB; Department of Developmental Biology, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands. van IJcken WFJ; Center for Biomics, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands. Gribnau JH; Department of Developmental Biology, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands. Atmodimedjo P; Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands. Dubbink HJ; Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands. MartensJWM; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands. Spaander MCW; Department of Gastroenterology & Hepatology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands. Wagner A; Department of Clinical Genetics, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2023 Sep 17; Vol. 15 (18). Date of Electronic Publication: 2023 Sep 17.
Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling.
Autorzy:
Angus L; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Cancer, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. Smid M; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Cancer, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. Wilting SM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Cancer, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. Bos MK; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Cancer, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. Steeghs N; Department of Medical Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.; Center for Personalized Cancer Treatment, 6500 HB Nijmegen, The Netherlands. Konings IRHM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands. Tjan-Heijnen VCG; Center for Personalized Cancer Treatment, 6500 HB Nijmegen, The Netherlands.; Department of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands. van Riel JMGH; Department of Internal Medicine, Elisabeth-TweeSteden Hospital, 5022 GC Tilburg, The Netherlands. van de Wouw AJ; Department of Medical Oncology, VieCuri Medical Center, 5912 BL Venlo, The Netherlands. Cpct Consortium; Center for Personalized Cancer Treatment, 6500 HB Nijmegen, The Netherlands. Cuppen E; Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands.; Hartwig Medical Foundation, 1098 XH Amsterdam, The Netherlands. Lolkema MP; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Cancer, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.; Center for Personalized Cancer Treatment, 6500 HB Nijmegen, The Netherlands. Jager A; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Cancer, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. Sleijfer S; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Cancer, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.; Center for Personalized Cancer Treatment, 6500 HB Nijmegen, The Netherlands. MartensJWM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Cancer, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2023 Sep 04; Vol. 15 (17). Date of Electronic Publication: 2023 Sep 04.
Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels.
Autorzy:
Jongbloed EM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. Jansen MPHM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. de Weerd V; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. Helmijr JA; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. Beaufort CM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. Reinders MJT; Delft Bioinformatics Lab, Delft University of Technology, Delft, The Netherlands. van Marion R; Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. van IJcken WFJ; Erasmus Center for Biomics, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands. Sonke GS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Konings IR; Department of Medical Oncology, Amsterdam UMC, location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Jager A; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. MartensJWM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. Wilting SM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. Makrodimitris S; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. .; Delft Bioinformatics Lab, Delft University of Technology, Delft, The Netherlands. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Jun 27; Vol. 13 (1), pp. 10424. Date of Electronic Publication: 2023 Jun 27.
Aberrant APOBEC3B Expression in Breast Cancer Is Linked to Proliferation and Cell Cycle Phase.
Autorzy:
Roelofs PA; Radiotherapy & OncoImmunology Laboratory, Department of Radiation Oncology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.; Department of Biochemistry, Molecular Biology and Biophysics, Masonic Cancer Center, Institute for Molecular Virology, and Center for Genome Engineering, University of Minnesota, Minneapolis, MN 55455, USA. Timmermans MAM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands. Stefanovska B; Department of Biochemistry, Molecular Biology and Biophysics, Masonic Cancer Center, Institute for Molecular Virology, and Center for Genome Engineering, University of Minnesota, Minneapolis, MN 55455, USA.; Department of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.; Howard Hughes Medical Institute, University of Texas Health San Antonio, San Antonio, TX 78229, USA. den Boestert MA; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands. van den Borne AWM; Radiotherapy & OncoImmunology Laboratory, Department of Radiation Oncology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands. Balcioglu HE; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands. Trapman AM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands. Harris RS; Department of Biochemistry, Molecular Biology and Biophysics, Masonic Cancer Center, Institute for Molecular Virology, and Center for Genome Engineering, University of Minnesota, Minneapolis, MN 55455, USA.; Department of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.; Howard Hughes Medical Institute, University of Texas Health San Antonio, San Antonio, TX 78229, USA. MartensJWM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands. Span PN; Radiotherapy & OncoImmunology Laboratory, Department of Radiation Oncology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Pokaż więcej
Źródło:
Cells [Cells] 2023 Apr 18; Vol. 12 (8). Date of Electronic Publication: 2023 Apr 18.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
A Compendium of AR Splice Variants in Metastatic Castration-Resistant Prostate Cancer.
Autorzy:
Isebia KT; Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 Rotterdam, The Netherlands. Lolkema MP; Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 Rotterdam, The Netherlands. Jenster G; Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 Rotterdam, The Netherlands. de Wit R; Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 Rotterdam, The Netherlands. MartensJWM; Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 Rotterdam, The Netherlands. van Riet J; Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 Rotterdam, The Netherlands.; Division of AI in Oncology, German Cancer Research Centre DKFZ, 69120 Heidelberg, Germany.
Methylated Cell-Free DNA Sequencing (MeD-seq) of LpnPI Digested Fragments to Identify Early Progression in Metastatic Renal Cell Carcinoma Patients on Watchful Waiting.
Autorzy:
Bos MK; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. Verhoeff SR; Department of Medical Oncology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands. Oosting SF; Department of Medical Oncology, University Medical Centre Groningen, 9713 GZ Groningen, The Netherlands. Menke-van der Houven van Oordt WC; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HZ Amsterdam, The Netherlands. Boers RG; Department of Developmental Biology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands. Boers JB; Department of Developmental Biology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands. Gribnau J; Department of Developmental Biology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands. MartensJWM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. Sleijfer S; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands. Wilting SM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2023 Feb 21; Vol. 15 (5). Date of Electronic Publication: 2023 Feb 21.
GRHL2-controlled gene expression networks in luminal breast cancer.
Autorzy:
Wang Z; Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands. Coban B; Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands. Wu H; Department of Human Genetics, Leiden University Medical Centre, Leiden, The Netherlands. Chouaref J; Department of Human Genetics, Leiden University Medical Centre, Leiden, The Netherlands. Daxinger L; Department of Human Genetics, Leiden University Medical Centre, Leiden, The Netherlands. Paulsen MT; Departments of Radiation Oncology and Environmental Health Sciences, University of Michigan Medical School, Ann Arbor, MI, USA. Ljungman M; Departments of Radiation Oncology and Environmental Health Sciences, University of Michigan Medical School, Ann Arbor, MI, USA. Smid M; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. MartensJWM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. Danen EHJ; Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands. .
Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers.
Autorzy:
Hakkaart C; Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand. Pearson JF; Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand. Marquart L; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.; School of Public Health, University of Queensland, Brisbane, Australia. Dennis J; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. Wiggins GAR; Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand. Barnes DR; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. Robinson BA; Department of Medicine, University of Otago, Christchurch, New Zealand.; Canterbury Regional Cancer and Haematology Service, Canterbury District Health Board, Christchurch Hospital, Christchurch, New Zealand. Mace PD; Department of Biochemistry, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand. Aittomäki K; Department of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland. Andrulis IL; Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada. Arun BK; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Azzollini J; Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy. Balmaña J; Hereditary cancer Genetics Group, Vall d'Hebron Institute of Oncology, Vall d'Hebron Hospital Campus, Barcelona, Spain.; Department of Medical Oncology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. Barkardottir RB; Department of Pathology, Landspitali University Hospital, Reykjavik, Iceland.; BMC (Biomedical Centre), Faculty of Medicine, University of Iceland, Reykjavik, Iceland. Belhadj S; Clinical Genetics Research Lab, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Berger L; Department of Clinical Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Blok MJ; Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands. Boonen SE; Department of Clinical Genetics, Odense University Hospital, Odence C, Denmark. Borde J; Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Bradbury AR; Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. Brunet J; Hereditary Cancer Program, Catalan Institute of Oncology (ICO), ONCOBELL-IDIBELL-IGTP, CIBERONC, Barcelona, Spain. Buys SS; Department of Medicine, Huntsman Cancer Institute, Salt Lake City, UT, USA. Caligo MA; SOD Genetica Molecolare, University Hospital, Pisa, Italy. Campbell I; Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia. Chung WK; Departments of Pediatrics and Medicine, Columbia University, New York, NY, USA. Claes KBM; Centre for Medical Genetics, Ghent University Hospital, Gent, Belgium. Collonge-Rame MA; Service de Génétique Biologique, CHRU de Besançon, Besançon, France. Cook J; Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield, UK. Cosgrove C; Gynecologic Oncology, Translational Therapeutics, Department of Obstetrics and Gynecology, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. Couch FJ; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Daly MB; Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA. Dandiker S; Clinical Genetics Research Lab, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Davidson R; Department of Clinical Genetics, Queen Elizabeth University Hospital, Glasgow, UK. de la Hoya M; Molecular Oncology Laboratory, CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, Spain. de Putter R; Centre for Medical Genetics, Ghent University Hospital, Gent, Belgium. Delnatte C; Oncogénétique, Institut de Cancérologie de l'Ouest siteRené Gauducheau, Saint Herblain, France. Dhawan M; Cancer Genetics and Prevention Program, University of California San Francisco, San Francisco, CA, USA. Diez O; Hereditary cancer Genetics Group, Vall d'Hebron Institute of Oncology, Vall d'Hebron Hospital Campus, Barcelona, Spain.; Area of Clinical and Molecular Genetics, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. Ding YC; Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA. Domchek SM; Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. Donaldson A; Clinical Genetics Department, St Michael's Hospital, Bristol, UK. Eason J; Nottingham Clinical Genetics Service, Nottingham University Hospitals NHS Trust, Nottingham, UK. Easton DF; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK. Ehrencrona H; Department of Clinical Genetics and Pathology, Laboratory Medicine, Skåne University Hospital, Lund, Sweden.; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden. Engel C; Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.; LIFE - Leipzig Research Centre for Civilization Diseases, University of Leipzig, Leipzig, Germany. Evans DG; Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.; North West Genomics Laboratory Hub, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. Faust U; Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany. Feliubadaló L; Hereditary Cancer Program, Catalan Institute of Oncology (ICO), ONCOBELL-IDIBELL-IGTP, CIBERONC, Barcelona, Spain. Fostira F; Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research 'Demokritos', Athens, Greece. Friedman E; The Susanne Levy Gertner Oncogenetics Unit, Chaim Sheba Medical Center, Ramat Gan, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel. Frone M; Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. Frost D; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. Garber J; Cancer Risk and Prevention Clinic, Dana-Farber Cancer Institute, Boston, MA, USA. Gayther SA; Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Gehrig A; Department of Human Genetics, University Würzburg, Würzburg, Germany. Gesta P; Service Régional Oncogénétique Poitou-Charentes, CH Niort, Niort, France. Godwin AK; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA. Goldgar DE; Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA. Greene MH; Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. Hahnen E; Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Hake CR; Waukesha Memorial Hospital-Pro Health Care, Waukesha, USA. Hamann U; Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. Hansen TVO; Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Hauke J; Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Hentschel J; Institute of Human Genetics, University Hospital Leipzig, Leipzig, Germany. Herold N; Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Honisch E; Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. Hulick PJ; Center for Medical Genetics, NorthShore University HealthSystem, Evanston, IL, USA.; The University of Chicago Pritzker School of Medicine, Chicago, IL, USA. Imyanitov EN; N.N. Petrov Institute of Oncology, St. Petersburg, Russia. Isaacs C; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. Izatt L; Clinical Genetics, Guy's and St Thomas' NHS Foundation Trust, London, UK. Izquierdo A; Hereditary Cancer Program, Catalan Institute of Oncology (ICO), ONCOBELL-IDIBELL-IGTP, CIBERONC, Barcelona, Spain. Jakubowska A; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.; Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland. James PA; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.; Parkville Familial Cancer Centre, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia. Janavicius R; Faculty of Medicine, Institute of Biomedical Sciences, Dept. Of Human and Medical Genetics, Vilnius University, Vilnius, Lithuania.; State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania. John EM; Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, USA.; Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. Joseph V; Clinical Genetics Research Lab, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Karlan BY; David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, CA, USA. Kemp Z; Breast and Cancer Genetics Units, The Royal Marsden NHS Foundation Trust, London, UK. Kirk J; Familial Cancer Service, Weatmead Hospital, Wentworthville, New South Wales, Australia. Konstantopoulou I; Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research 'Demokritos', Athens, Greece. Koudijs M; Department of Medical Genetics, University Medical Center, Utrecht, The Netherlands. Kwong A; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong, China.; Department of Surgery, The University of Hong Kong, Hong Kong, China.; Department of Surgery and Cancer Genetics Center, Hong Kong Sanatorium and Hospital, Hong Kong, China. Laitman Y; The Susanne Levy Gertner Oncogenetics Unit, Chaim Sheba Medical Center, Ramat Gan, Israel. Lalloo F; Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA. Lasset C; Unité de Prévention et d'Epidémiologie Génétique, Centre Léon Bérard, Lyon, France. Lautrup C; Department of Clinical Genetics, Aarhus University Hospital, Aarhus N, Denmark. Lazaro C; Hereditary Cancer Program, Catalan Institute of Oncology (ICO), ONCOBELL-IDIBELL-IGTP, CIBERONC, Barcelona, Spain. Legrand C; Département de Génétique, CHU de Grenoble, Grenoble, France. Leslie G; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. Lesueur F; Genetic Epidemiology of Cancer team, Inserm U900, Paris, France.; Institut Curie, Paris, France.; Mines ParisTech, Fontainebleau, France. Mai PL; Magee-Womens Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Manoukian S; Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy. Mari V; Département d'Hématologie-Oncologie Médicale, Centre Antoine Lacassagne, Nice, France. MartensJWM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. McGuffog L; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. Mebirouk N; Genetic Epidemiology of Cancer team, Inserm U900, Paris, France.; Institut Curie, Paris, France.; Mines ParisTech, Fontainebleau, France. Meindl A; Department of Gynecology and Obstetrics, University of Munich, Campus Großhadern, Munich, Germany. Miller A; NRG Oncology, Statistics and Data Management Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Montagna M; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy. Moserle L; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy. Mouret-Fourme E; Service de Génétique, Institut Curie, Paris, France. Musgrave H; Department of Clinical Genetics, Yorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds, UK. Nambot S; Unité d'oncogénétique, Centre de Lutte Contre le Cancer, Centre Georges-François Leclerc, Dijon, France. Nathanson KL; Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. Neuhausen SL; Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA. Nevanlinna H; Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. Yie JNY; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.; Cancer Genetics Service, National Cancer Centre, Singapore, Singapore. Nguyen-Dumont T; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.; Department of Clinical Pathology, The University of Melbourne, Melbourne, Victoria, Australia. Nikitina-Zake L; Latvian Biomedical Research and Study Centre, Riga, Latvia. Offit K; Clinical Genetics Research Lab, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Olah E; Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary. Olopade OI; Center for Clinical Cancer Genetics, The University of Chicago, Chicago, IL, USA. Osorio A; Familial Cancer Clinical Unit, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO) and Spanish Network on Rare Diseases (CIBERER), Madrid, Spain. Ott CE; Institute of Medical Genetics and Human Genetics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany. Park SK; Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea.; Integrated Major in Innovative Medical Science, Seoul National University College of Medicine, Seoul, South Korea.; Cancer Research Institute, Seoul National University, Seoul, Korea. Parsons MT; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. Pedersen IS; Molecular Diagnostics, Aalborg University Hospital, Aalborg, Denmark.; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Peixoto A; Department of Genetics, Portuguese Oncology Institute, Porto, Portugal. Perez-Segura P; Molecular Oncology Laboratory, CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, Spain. Peterlongo P; Genome Diagnostics Program, IFOM ETS - the AIRC Institute of Molecular Oncology, Milan, Italy. Pocza T; Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary. Radice P; Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy. Ramser J; Division of Gynaecology and Obstetrics, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany. Rantala J; Clinical Genetics, Karolinska Institutet, Stockholm, Sweden. Rodriguez GC; Division of Gynecologic Oncology, NorthShore University HealthSystem, University of Chicago, Evanston, IL, USA. Rønlund K; Department of Clinical Genetics, University Hospital of Southern Denmark, Vejle Hospital, Vejle, Denmark. Rosenberg EH; Department of Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Rossing M; Center for Genomic Medicine, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. Schmutzler RK; Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Shah PD; Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. Sharif S; West Midlands Regional Genetics Service, Birmingham Women's Hospital Healthcare NHS Trust, Birmingham, UK. Sharma P; Department of Internal Medicine, Division of Medical Oncology, University of Kansas Medical Center, Westwood, KS, USA. Side LE; Princess Anne Hospital, Southampton, UK. Simard J; Genomics Center, Centre Hospitalier Universitaire de Québec - Université Laval Research Center, Québec City, QC, Canada. Singer CF; Dept of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Snape K; Medical Genetics Unit, St George's, University of London, London, UK. Steinemann D; Institute of Human Genetics, Hannover Medical School, Hannover, Germany. Stoppa-Lyonnet D; Service de Génétique, Institut Curie, Paris, France.; Department of Tumour Biology, INSERM U830, Paris, France.; Université Paris Cité, Paris, France. Sutter C; Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany. Tan YY; Dept of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Teixeira MR; Department of Genetics, Portuguese Oncology Institute, Porto, Portugal.; Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal. Teo SH; Breast Cancer Research Programme, Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia.; Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. Thomassen M; Department of Clinical Genetics, Odense University Hospital, Odence C, Denmark. Thull DL; Department of Medicine, Magee-Womens Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Tischkowitz M; Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill University, Montréal, QC, Canada.; Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK. Toland AE; Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH, USA. Trainer AH; Parkville Familial Cancer Centre, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.; Department of medicine, University Of Melbourne, Melbourne, Victoria, Australia. Tripathi V; South East Thames Regional Genetics Service, Guy's and St Thomas' NHS Foundation Trust, London, UK. Tung N; Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA. van Engelen K; Department of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands. van Rensburg EJ; Department of Genetics, University of Pretoria, Arcadia, South Africa. Vega A; Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain.; Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain.; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain. Viel A; Division of Functional onco-genomics and genetics, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy. Walker L; Oxford Regional Genetics Service, Churchill Hospital, Oxford, UK. Weitzel JN; Latin American School of Oncology, Tuxtla Gutiérrez, Chiapas, Mexico. Wevers MR; Radboud University Medical Center, Nijmegen, Netherlands. Chenevix-Trench G; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. Spurdle AB; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. Antoniou AC; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. Walker LC; Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand. .
Characterizing Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles in Metastatic Castration-Naive and Castration-Resistant Prostate Cancer Patients.
Autorzy:
Isebia KT; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. Dathathri E; Department of Medical Cell Biophysics, Technical Medical Center, Faculty of Science and Technology, University of Twente, 7522 NB Enschede, The Netherlands. Verschoor N; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. Nanou A; Department of Medical Cell Biophysics, Technical Medical Center, Faculty of Science and Technology, University of Twente, 7522 NB Enschede, The Netherlands. De Jong AC; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. Coumans FAW; Department of Medical Cell Biophysics, Technical Medical Center, Faculty of Science and Technology, University of Twente, 7522 NB Enschede, The Netherlands. Terstappen LWMM; Department of Medical Cell Biophysics, Technical Medical Center, Faculty of Science and Technology, University of Twente, 7522 NB Enschede, The Netherlands. Kraan J; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. MartensJWM; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. Bansal R; Department of Medical Cell Biophysics, Technical Medical Center, Faculty of Science and Technology, University of Twente, 7522 NB Enschede, The Netherlands. Lolkema MP; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2022 Sep 10; Vol. 14 (18). Date of Electronic Publication: 2022 Sep 10.
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases.
Autorzy:
van den Ende NS; Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands. Smid M; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands. Timmermans A; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands. van Brakel JB; Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands.; Department of Pathology, Skåne University Hospital, Malmö, Sweden. Hansum T; Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands.; Department of Pathology, Reinier Haga MDC, Delft, The Netherlands. Foekens R; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands. Trapman AMAC; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands. Heemskerk-Gerritsen BAM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands. Jager A; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands. MartensJWM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands. van Deurzen CHM; Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Jul 28; Vol. 12 (1), pp. 12974. Date of Electronic Publication: 2022 Jul 28.
Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry.
Autorzy:
Dumont M; Genomics Center, CHU de Québec-Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, QC GIV 4G2, Canada. Weber-Lassalle N; Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany. Joly-Beauparlant C; Genomics Center, CHU de Québec-Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, QC GIV 4G2, Canada. Ernst C; Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany. Droit A; Genomics Center, CHU de Québec-Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, QC GIV 4G2, Canada. Feng BJ; Department of Dermatology, University of Utah, Salt Lake City, UT 84103, USA.; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA. Dubois S; Genomics Center, CHU de Québec-Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, QC GIV 4G2, Canada. Collin-Deschesnes AC; Genomics Center, CHU de Québec-Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, QC GIV 4G2, Canada. Soucy P; Genomics Center, CHU de Québec-Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, QC GIV 4G2, Canada. Vallée M; Genomics Center, CHU de Québec-Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, QC GIV 4G2, Canada. Fournier F; Genomics Center, CHU de Québec-Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, QC GIV 4G2, Canada. Lemaçon A; Genomics Center, CHU de Québec-Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, QC GIV 4G2, Canada. Adank MA; Family Cancer Clinic, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 Amsterdam, The Netherlands. Allen J; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK. Altmüller J; Cologne Center for Genomics (CCG), Faculty of Medicine, University Hospital Cologne, University of Cologne, 50931 Cologne, Germany. Arnold N; Institute of Clinical Molecular Biology, Department of Gynaecology and Obstetrics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, 24105 Kiel, Germany. Ausems MGEM; Division Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Center Utrecht, 3584 Utrecht, The Netherlands. Berutti R; Institute of Human Genetics, Technische Universität München, 81675 Munich, Germany. Bolla MK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK. Bull S; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada.; Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada. Carvalho S; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK. Cornelissen S; Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 Amsterdam, The Netherlands. Dufault MR; Precision Medicine and Computational Biology, Sanofi Genzyme, Cambridge, MA 02142, USA. Dunning AM; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK. Engel C; Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, 04107 Leipzig, Germany. Gehrig A; Centre of Familial Breast and Ovarian Cancer, Department of Medical Genetics, Institute of Human Genetics, University of Würzburg, 97074 Würzburg, Germany. Geurts-Giele WRR; Department of Clinical Genetics, Erasmus University Medical Center, 3015 Rotterdam, The Netherlands. Gieger C; Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany.; Research Unit Molecular Epidemiology, Helmholtz Zentrum München, German Research Centre for Environmental Health, 85764 Neuherberg, Germany. Green J; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada. Hackmann K; Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany. Helmy M; The Donnelly Centre, University of Toronto, Toronto, ON M5S 3E1, Canada.; Bioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), Singapore 138632, Singapore.; Department of Computer Science, Lakehead University, Thunder Bay, ON P7B 5E1, Canada. Hentschel J; Institute of Human Genetics, University Leipzig, 04103 Leipzig, Germany. Hogervorst FBL; Family Cancer Clinic, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 Amsterdam, The Netherlands. Hollestelle A; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 Rotterdam, The Netherlands. Hooning MJ; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 Rotterdam, The Netherlands. Horváth J; Institute of Human Genetics, University of Münster, 48149 Münster, Germany. Ikram MA; Department of Epidemiology, Erasmus MC University Medical Center, 3015 Rotterdam, The Netherlands. Kaulfuß S; Institute of Human Genetics, University Medical Center Göttingen, 37075 Göttingen, Germany. Keeman R; Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 Amsterdam, The Netherlands. Kuang D; Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada.; The Donnelly Centre, University of Toronto, Toronto, ON M5S 3E1, Canada. Luccarini C; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK. Maier W; German Center for Neurodegenerative Diseases (DZNE), Department of Neurodegenerative Diseases and Geriatric Psychiatry, Medical Faculty, University Hospital Bonn, 53127 Bonn, Germany. MartensJWM; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 Rotterdam, The Netherlands. Niederacher D; Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany. Nürnberg P; Center for Molecular Medicine Cologne (CMMC), Cologne Center for Genomics (CCG), Faculty of Medicine, University Hospital Cologne, University of Cologne, 50931 Cologne, Germany. Ott CE; Institute of Medical Genetics and Human Genetics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 13353 Berlin, Germany. Peters A; Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany.; Department of Epidemiology, Institute for Medical Information Processing, Biometry and Epidemiology, Medical Faculty, Ludwig-Maximilians-Universität München, 80539 Munich, Germany. Pharoah PDP; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK.; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK. Ramirez A; Division for Neurogenetics and Molecular Psychiatry, Medical Faculty, University of Cologne, 50937 Cologne, Germany. Ramser J; Division of Gynaecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität München, 81675 Munich, Germany. Riedel-Heller S; Institute of Social Medicine, Occupational Health and Public Health, Faculty of Medicine, University of Leipzig, 04103 Leipzig, Germany. Schmidt G; Institute of Human Genetics, Hannover Medical School, 30625 Hannover, Germany. Shah M; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK. Scherer M; Department of Primary Medical Care, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany. Stäbler A; Institute of Medical Genetics and Applied Genomics, University of Tübingen, 72076 Tübingen, Germany. Strom TM; Institute of Human Genetics, Technische Universität München, 81675 Munich, Germany. Sutter C; Institute of Human Genetics, University Hospital Heidelberg, 69120 Heidelberg, Germany. Thiele H; Cologne Center for Genomics (CCG), Faculty of Medicine, University Hospital Cologne, University of Cologne, 50931 Cologne, Germany. van Asperen CJ; Department of Clinical Genetics, Leiden University Medical Center, 2333 Leiden, The Netherlands. van der Kolk L; Family Cancer Clinic, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 Amsterdam, The Netherlands. van der Luijt RB; Department of Clinical Genetics, Leiden University Medical Center, 2333 Leiden, The Netherlands.; Department of Medical Genetics, University Medical Center, 3584 Utrecht, The Netherlands. Volk AE; Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany. Wagner M; Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, 53127 Bonn, Germany. Waisfisz Q; Department of Human Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 Amsterdam, The Netherlands. Wang Q; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK. Wang-Gohrke S; Department of Gynaecology and Obstetrics, University of Ulm, 89081 Ulm, Germany. Weber BHF; Institute of Human Genetics, Regensburg University, 93053 Regensburg, Germany.; Institute of Clinical Human Genetics, University Hospital Regensburg, 93053 Regensburg, Germany. Genome Of The Netherlands Project Ghs Study Group Devilee P; Department of Pathology, Department of Human Genetics, Leiden University Medical Center, 2333 Leiden, The Netherlands. Tavtigian S; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.; Department of Oncological Sciences, University of Utah School of Medicine, Salt Lake City, UT 84132, USA. Bader GD; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada.; The Donnelly Centre, University of Toronto, Toronto, ON M5S 3E1, Canada.; Department of Computer Science, University of Toronto, Toronto, ON M5S 3E1, Canada.; Princess Margaret Research Institute, University Health Network, Toronto, ON M5G 0A3, Canada. Meindl A; Division of Gynaecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität München, 81675 Munich, Germany. Goldgar DE; Department of Dermatology, University of Utah, Salt Lake City, UT 84103, USA.; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA. Andrulis IL; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada. Schmutzler RK; Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany. Easton DF; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK.; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK. Schmidt MK; Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 Amsterdam, The Netherlands.; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 Amsterdam, The Netherlands. Hahnen E; Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany. Simard J; Genomics Center, CHU de Québec-Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, QC GIV 4G2, Canada.; Department of Molecular Medicine, Faculty of Medicine, Université Laval, Quebec, QC G1V 0A6, Canada.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2022 Jul 11; Vol. 14 (14). Date of Electronic Publication: 2022 Jul 11.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
